EUCTR2018-004055-20-FR进行中（未招募）1 期
Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free in Comparison with Verorab® and Imovax® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France
Sanofi Pasteur SA0 个研究点目标入组 640 人开始时间: 2019年2月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 640
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Men or women aged =18 years on the day of inclusion (= 18 years means from the day of the 18th birthday onwards, with no upper age limit).
- •- Able to attend all scheduled visits and to comply with all trial procedures.
- •- Body Mass Index (BMI): 18.5 Kg/m2 = BMI = 30 Kg/m2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 479
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •- Subject is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile.
- •- Participation at the time of study enrollment or, planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
- •- Receipt of any vaccine in the 4 weeks (28 days) preceding the first trial vaccination or planned receipt of any vaccine prior to Visit 7.
- •- Previous vaccination against rabies (in pre- or post-exposure regimen) with either the trial vaccines or another vaccine.
- •-Receipt of immune globulins, blood or blood-derived products in the past 3 months.
- •- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- •- At high risk for rabies exposure during the trial (veterinarians and their staff, animal handlers, rabies researchers, and certain laboratory workers, persons whose activities bring them into frequent contact with rabies virus or potentially rabid bats, raccoons, skunks, cats, dogs, or other species at risk for having rabies, people travelling where rabies is enzootic).
- •- Known systemic hypersensitivity to any of the vaccine or HRIG components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.
- •- Self-reported thrombocytopenia, contraindicating IM vaccination.
- •- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.
- •- Current alcohol or substance abuse that, in the opinion of the investigator, might interfere with the trial conduct of completion.
- •- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion.
- •- Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature = 38.0°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
- •- Personal history of Guillain-Barré syndrome.
- •- Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
研究者
相似试验
进行中（未招募）
1 期
Study of Purified Vero Rabies Vaccine Compared with Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of AdultsRabiesMedDRA version: 20.0Level: PTClassification code 10037742Term: RabiesSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-000973-22-Outside-EU/EEASanofi Pasteur SA
进行中（未招募）
不适用
Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies VaccineProphylactic Immunization against RabiesEUCTR2015-005194-20-Outside-EU/EEASanofi Pasteur SA816
进行中（未招募）
不适用
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis RegimeRabies infectionEUCTR2015-003203-30-Outside-EU/EEASanofi Pasteur SA342
进行中（未招募）
1 期
Immunogenicity of the Purified Vero Rabies Vaccine – Serum Free in Comparison with the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy AdultsEUCTR2009-009877-85-FRSanofi Pasteur SA385
已完成
3 期
Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in AdultsRabies (Healthy Volunteers)NCT03965962Sanofi Pasteur, a Sanofi Company640